Kyverna Therapeutics (KYTX) will present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase 1/2 studies and named patient treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback